Chimeric classical swine fever (CSF)-Japanese encephalitis (JE) viral replicon as a non-transmissible vaccine candidate against CSF and JE infections.

Authors:
Address: State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China.
Journal:

Publication:

abstract

A trans-complemented Chimeric CSF-JE virus replicon was constructed using an infectious cDNA clone of the CSF virus (CSFV) Alfort/187 strain. The CSFV E2 gene was deleted, and a fragment containing the region encoding a truncated envelope protein (tE, amino acid 292-402, domain III) of JE virus (JEV) was inserted into the resultant plasmid, pA187delE2, to generate the recombinant cDNA clone pA187delE2/JEV-tE. Porcine kidney 15 (PK15) cells that constitutively express the CSFV E2p7 proteins were then transfected with in vitro-transcribed RNA from pA187delE2/JEV-tE. As a result, the chimeric CSF-JE virus replicon particle (VRP), rv187delE2/JEV-tE, was rescued. In a mouse model, immunization with the chimeric CSF-JE VRP induced strong production of JEV-specific antibody and conferred protection against a lethal JEV challenge. Pigs immunized with CSF-JE VRP displayed strong anti-CSFV and anti-JEV antibody responses and protection against CSFV and JEV challenge infections. Our evidence suggests that E2-complemented CSF-JE VRP not only has potential as a live-attenuated non-transmissible vaccine candidate against CSF and JE but also serves as a potential DIVA (Differentiating Infected from Vaccinated Animals) vaccine for CSF in pigs. Together, our data suggest that the non-transmissible chimeric VRP expressing foreign antigenic proteins may represent a promising strategy for bivalent DIVA vaccine design.

Related Articles
Oronasal vaccination with classical swine fever virus (CSFV) replicon particles with either partial or complete deletion of the E2 gene induces partial protection against lethal challenge with highly virulent CSFV.
Vaccine. 2005
Oronasal vaccination with classical swine fever virus (CSFV) replicon particles with either partial or complete deletion of the E2 gene induces partial protection against lethal challenge with highly virulent CSFV.
Maurer R, Stettler P, Ruggli N, Hofmann MA, Tratschin JD. Vaccine. 2005 May 9; 23(25):3318-28.
Classical swine fever virus replicon particles lacking the Erns gene: a potential marker vaccine for intradermal application.
Vet Res. 2006
Classical swine fever virus replicon particles lacking the Erns gene: a potential marker vaccine for intradermal application.
Frey CF, Bauhofer O, Ruggli N, Summerfield A, Hofmann MA, Tratschin JD. Vet Res. 2006 Sep-Oct; 37(5):655-70. Epub 2006 Jun 17.
Experimental non-transmissible marker vaccines for classical swine fever (CSF) by trans-complementation of E(rns) or E2 of CSFV.
Vaccine. 2002
Experimental non-transmissible marker vaccines for classical swine fever (CSF) by trans-complementation of E(rns) or E2 of CSFV.
van Gennip HG, Bouma A, van Rijn PA, Widjojoatmodjo MN, Moormann RJ. Vaccine. 2002 Feb 22; 20(11-12):1544-56.
Review IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.
Expert Rev Vaccines. 2010
Review IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.
Appaiahgari MB, Vrati S. Expert Rev Vaccines. 2010 Dec; 9(12):1371-84.
Review Marker vaccine strategies and candidate CSFV marker vaccines.
Vaccine. 2007
Review Marker vaccine strategies and candidate CSFV marker vaccines.
Dong XN, Chen YH. Vaccine. 2007 Jan 4; 25(2):205-30. Epub 2006 Aug 7.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.